Streetbeat News

LQDA

Liquidia Corporation

https://www.liquidia.com

Industry

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Open

14.10

Mkt cap

1.2B

Volume

949K

High

14.47

P/E Ratio

-8.91

52-wk high

16.99

Low

14.05

Div yield

N/A

52-wk low

8.26

Liquidia has priced its public offering of 3.49 million shares at $7.16 per share, aiming to raise total gross proceeds of $25 million. The offering is anticipated to close on December 14, 2023, pending customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 12:17 pm

The U.S. Court of Appeals for the Federal Circuit is currently live streaming proceedings from Courtroom 203. The live stream is available on YouTube. Companies such as CVS, GOOGL, and LQDA may be mentioned during the stream.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 4:34 pm

Needham analyst Serge Belanger has reiterated a 'Buy' rating on Liquidia (NASDAQ:LQDA) and maintained a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 9:50 am

Liquidia reported Q3 earnings per share (EPS) of $(0.24), compared to $(0.14) year over year (YoY). The company's sales were $3.68M, missing the estimate of $4.33M.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 11:33 am

Liquidia (NASDAQ:LQDA) is set to announce its latest quarterly earnings report on November 7, 2023. Analysts estimate an EPS of $-0.21. The company's past performance shows a trend of missing EPS estimates, which has led to share price drops. The stock is currently trading at $6.65, up 32.26% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 6:01 pm

Needham analyst Serge Belanger has reinstated Liquidia (NASDAQ:LQDA) with a Buy rating and maintained the price target at $18.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:20 pm

Liquidia has announced that the Generic Drug Administration (GDA) has accepted for review the company's amendment to the Tentatively Approved New Drug Application (NDA) for YUTREPIA.

Portfolio Pulse from Bill Haddad

September 25, 2023 | 8:11 pm

United Therapeutics Corporation has filed a lawsuit alleging infringement of its Tyvaso patent, which has already been declared invalid by the U.S. Patent Office.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 8:32 pm

Wedbush analyst Andreas Argyrides has reiterated an 'Underperform' rating on Liquidia (NASDAQ:LQDA) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 12:16 pm

Several stocks experienced significant price movements in Friday's mid-day session. Amyris, Inc. (AMRS) and Proterra Inc. (PTRA) both filed for Chapter 11 bankruptcy, causing their shares to jump 179.1% and 37% respectively. Rigetti Computing, Inc. (RGTI), Telesat Corporation (TSAT), Ouster, Inc. (OUST), Evolv Technologies Holdings, Inc. (EVLV), Innodata Inc. (INOD), Apyx Medical Corporation (APYX), IonQ, Inc. (IONQ), 2U, Inc. (TWOU), Groupon, Inc. (GRPN), Bitdeer Technologies Group (BTDR), MicroCloud Hologram Inc. (HOLO), Tango Therapeutics, Inc. (TNGX), Eton Pharmaceuticals, Inc. (ETON), ModivCare Inc. (MODV), WeWork Inc. (WE), Arco Platform Limited (ARCE), Semler Scientific, Inc. (SMLR), Soho House & Co Inc. (SHCO), CleanSpark, Inc. (CLSK), Consolidated Water Co. Ltd. (CWCO), Apellis Pharmaceuticals, Inc. (APLS), Pagaya Technologies Ltd. (PGY), Erasca, Inc. (ERAS), NextNav Inc. (NN), and Holley Inc. (HLLY) all reported better-than-expected results, causing their shares to rise. Cano Health, Inc. (CANO) reported worse-than-expected results and is pursuing a sale process, causing its shares to dip 70.7%. Yield10 Bioscience, Inc. (YTEN) announced pricing of a $3.7 million public offering, causing its shares to fall 58.1%. Maxeon Solar Technologies, Ltd. (MAXN) reported mixed results and issued FY23 revenue guidance below estimates, causing its shares to fall 32%.

Portfolio Pulse from Lisa Levin

August 11, 2023 | 5:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.